| Study, Year |
Study Period |
Number of participants |
Main Inclusion Criteria |
Main Exclusion Criteria |
Treatment |
Control |
| Jeong, 2009 |
12 months |
77 |
Men ≥50 years with moderate to severe BPH, on stable dose of uroselective alpha-blockers, prostate gland ≥ 25 cm3 |
Chronic UTI, prostate/testicular surgery, prostate cancer, abnormal PSA, high probability of urinary obstruction likely to require surgery, AUR, chronically large postvoid residual urine volume, history of 5AR inhibitor |
Dutasteride 0.5mg + alfuzosin 10mg (or tamsulosin 0.2mg) daily |
Finasteride 5mg + alfuzosin 10mg (or tamsulosin 0.2mg) daily |
| Li, 2013 |
6 months |
72 |
Men with BPH, IPSS greater than 13, Qmax less than 15mL/s, PSA less than 4µg/L, urine volume less than 150mL/urination |
Prostate cancer, urethra narrowing, bladder stone, urinary infections, neurogenic bladder, lower urinary track blockage/restriction, surgical interventions, BPH meds within 4 weeks prior to start of study, heart/lung/liver/kidney insufficiency |
Dutasteride 0.5mg daily |
Finasteride 5mg daily |
| Mohanty, 2006 |
6 months |
100 |
Men 40-80 years with BPH, no indication for surgery |
Suspected or diagnosed prostate cancer |
Dutasteride 0.5mg + tamsulosin 0.4mg daily at night |
Finasteride 5mg + tamsulosin 0.4mg daily at night |
| Nickel, 2011 |
12 months |
1630 |
Men ≥50 years with BPH, AUA-SI ≥ 12 points, prostate volume ≥ 30 cm3, Qmax<15mL/s, minimum voided volume ≥ 125mL |
Post-void residual volume >250mL, history or evidence of prostate cancer, previous prostatic surgery or invasive BPH treatment procedure, history of AUR in the past 3 months, PSA <1.5 ng/mL or 10 ng/mL, use of 5ARIs, use of alpha blockers within 2 weeks of screening visit and throughout study |
Dutasteride 0.5mg daily |
Finasteride 5mg daily |
|
